Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis

Overview

Journal Rheumatol Ther

Specialty Rehabilitation Medicine

Date 2017 Jul 29

PMID 28752316

Citations 12

Authors

Roberta Gualtierotti

Nicola Ughi

Giovanni Marfia

Francesca Ingegnoli

Affiliations

Soon will be listed here.

Abstract

Cardiovascular (CV) comorbidities are a frequent extra-articular manifestation of rheumatoid arthritis (RA). Cardiovascular disease (CVD) with accelerated atherosclerosis is a major cause of morbidity and mortality in patients with RA. Subclinical CVD may be present since the early phase of RA. Not only traditional but also non-traditional CV risk factors are involved in the pathogenesis of RA-related CVD. Due to the lack of specifically designed randomized clinical trials, it is still unclear which tools to use to perform CV risk assessment, how to interpret the results and which interventions are appropriate in RA patients both to prevent and to manage CVD. Based on the available evidence, we propose a practical approach.

Citing Articles

Cardiovascular Risk Management In Patients With Rheumatoid Arthritis: A Systematic Review.

Singh T, Laxmiraj B, Chukka R, Noor T Cureus. 2024; 16(4):e58409.

PMID: 38756324 PMC: 11098443. DOI: 10.7759/cureus.58409.

Remotely Supervised Weight Loss and Exercise Training to Improve Rheumatoid Arthritis Cardiovascular Risk: Rationale and Design of the Supervised Weight Loss Plus Exercise Training-Rheumatoid Arthritis Trial.

Andonian B, Ross L, Zidek A, Fos L, Piner L, Johnson J ACR Open Rheumatol. 2023; 5(5):252-263.

PMID: 36992545 PMC: 10184018. DOI: 10.1002/acr2.11536.

Uncovering mechanisms of brain inflammation in Alzheimer's disease with APOE4: Application of single cell-type lipidomics.

Asante I, Louie S, Yassine H Ann N Y Acad Sci. 2022; 1518(1):84-105.

PMID: 36200578 PMC: 10092192. DOI: 10.1111/nyas.14907.

Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes.

Taylor P, Cerinic M, Alten R, Avouac J, Westhovens R Ther Adv Musculoskelet Dis. 2022; 14:1759720X221114101.

PMID: 35991524 PMC: 9386864. DOI: 10.1177/1759720X221114101.

Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: a cross-sectional real-life study.

Vicente G, Pereira I, Werner de Castro G, Mota L, Carnieletto A, de Souza D Adv Rheumatol. 2021; 61(1):38.

PMID: 34172097 DOI: 10.1186/s42358-021-00186-4.

References

Ozturk K . Arterial stiffness and ankle brachial index in patients with rheumatoid arthritis and inflammatory bowel disease. J Inflamm (Lond). 2016; 13:2. PMC: 4705750. DOI: 10.1186/s12950-016-0110-y. View

Metsios G, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten J, Nightingale P, Sandoo A, Dimitroulas T . Individualised exercise improves endothelial function in patients with rheumatoid arthritis. Ann Rheum Dis. 2013; 73(4):748-51. DOI: 10.1136/annrheumdis-2013-203291. View

Libby P, Ridker P, Hansson G . Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473(7347):317-25. DOI: 10.1038/nature10146. View

Ingegnoli F, Fantini F, Griffini S, Soldi A, Meroni P, Cugno M . Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol. 2010; 28(2):254-7. View

Gualtierotti R, Ingegnoli F, Griffini S, Grovetti E, Meroni P, Cugno M . Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade. Clin Exp Rheumatol. 2016; 34(3):451-8. View

Ajeganova S, de Faire U, Jogestrand T, Frostegard J, Hafstrom I . Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis -- an inception cohort study. J Rheumatol. 2012; 39(6):1146-54. DOI: 10.3899/jrheum.111334. View

Bacchiega B, Bacchiega A, Usnayo M, Bedirian R, Singh G, da Rocha Castelar Pinheiro G . Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study. J Am Heart Assoc. 2017; 6(3). PMC: 5524026. DOI: 10.1161/JAHA.116.005038. View

Souto A, Salgado E, Maneiro J, Mera A, Carmona L, Gomez-Reino J . Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol. 2014; 67(1):117-27. DOI: 10.1002/art.38894. View

Crea F, Camici P, Merz C . Coronary microvascular dysfunction: an update. Eur Heart J. 2013; 35(17):1101-11. PMC: 4006091. DOI: 10.1093/eurheartj/eht513. View

10.

Avina-Zubieta J, Thomas J, Sadatsafavi M, Lehman A, Lacaille D . Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012; 71(9):1524-9. DOI: 10.1136/annrheumdis-2011-200726. View

11.

Scanlon E, Mankad R, Crowson C, Kullo I, Mulvagh S, Matteson E . Cardiovascular risk assessment in patients with rheumatoid arthritis: a correlative study of noninvasive arterial health testing. Clin Rheumatol. 2016; 36(4):763-771. PMC: 5366091. DOI: 10.1007/s10067-016-3515-3. View

12.

Hollan I, Meroni P, Ahearn J, Cohen Tervaert J, Curran S, Goodyear C . Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 2013; 12(10):1004-15. DOI: 10.1016/j.autrev.2013.03.013. View

13.

Lv S, Liu Y, Zou Z, Li F, Zhao S, Shi R . The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol. 2014; 33(1):69-76. View

14.

Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J . Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet. 2013; 382(9905):1629-37. DOI: 10.1016/S0140-6736(13)61842-5. View

15.

Hollan I, Dessein P, Ronda N, Wasko M, Svenungsson E, Agewall S . Prevention of cardiovascular disease in rheumatoid arthritis. Autoimmun Rev. 2015; 14(10):952-69. DOI: 10.1016/j.autrev.2015.06.004. View

16.

Giles J, Allison M, Blumenthal R, Post W, Gelber A, Petri M . Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum. 2010; 62(11):3173-82. PMC: 2962724. DOI: 10.1002/art.27629. View

17.

Agca R, Heslinga S, Rollefstad S, Heslinga M, McInnes I, Peters M . EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2016; 76(1):17-28. DOI: 10.1136/annrheumdis-2016-209775. View

18.

Greulich S, Kitterer D, Kurmann R, Henes J, Latus J, Gloekler S . Cardiac involvement in patients with rheumatic disorders: Data of the RHEU-M(A)R study. Int J Cardiol. 2016; 224:37-49. DOI: 10.1016/j.ijcard.2016.08.298. View

19.

Sodergren A, Karp K, Bengtsson C, Moller B, Rantapaa-Dahlqvist S, Wallberg-Jonsson S . Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?. Biomed Res Int. 2015; 2015:673018. PMC: 4609366. DOI: 10.1155/2015/673018. View

20.

Solomon D, Greenberg J, Curtis J, Liu M, Farkouh M, Tsao P . Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study. Arthritis Rheumatol. 2015; 67(8):1995-2003. DOI: 10.1002/art.39195. View